Welcome to our dedicated page for Avadel Pharmaceu news (Ticker: AVDL), a resource for investors and traders seeking the latest updates and insights on Avadel Pharmaceu stock.
Avadel Pharmaceuticals plc was a commercial-stage biopharmaceutical company focused on sleep medicine before its acquisition by Alkermes plc. Its company updates centered on LUMRYZ, an FDA-approved sodium oxybate extended-release oral suspension for cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy.
Recurring developments included LUMRYZ commercialization, clinical and regulatory disclosures for the REVITALYZ trial in idiopathic hypersomnia, operating and financial results, material agreements, shareholder voting matters, governance items and capital-structure changes tied to its public-company status and completed acquisition.
Avadel Pharmaceuticals reported strong financial results for the first quarter of 2024, generating $27.2 million in net revenue from LUMRYZ sales. The company enrolled over 2,800 patients in RYZUP patient support services, with more than 1,700 patients initiating therapy. Avadel is seeking to expand LUMRYZ usage through a sNDA for pediatric narcolepsy and plans to start a Phase 3 trial for idiopathic hypersomnia. Despite a net loss of $27.3 million, Avadel holds $88.8 million in cash and marketable securities as of March 31, 2024.
Avadel Pharmaceuticals plc will host a conference call and live webcast on May 8, 2024, to provide a corporate update and discuss the financial results for the first quarter of 2024. Investors can access the call through dial-in numbers or the company's website.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.